| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6093575 | Gastroenterology | 2015 | 13 Pages |
Abstract
Targeting patients' infliximab TCs to 3-7 μg/mL results in a more efficient use of the drug. After dose optimization, continued concentration-based dosing was not superior to clinically based dosing for achieving remission after 1 year, but was associated with fewer flares during the course of treatment. ClinicalTrialsRegister.eu number: 2011-002061-38.
Keywords
Partial Mayo scoreTNFPMSATIHBIIBDIQRQALYMonoclonal antibodyantibodies to infliximabCrohn’s diseaseInflammatory bowel diseaseTrough concentrationQuality Adjusted Life YearsHarvey-Bradshaw IndexPharmacokineticstumor necrosis factorinterquartile rangetherapeutic drug monitoringC-reactive proteinCRPPersonalized medicineUlcerative colitis
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Niels Vande Casteele, Marc Ferrante, Gert Van Assche, Vera Ballet, Griet Compernolle, Kristel Van Steen, Steven Simoens, Paul Rutgeerts, Ann Gils, Séverine Vermeire,